Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
7.75
-0.20 (-2.52%)
At close: Sep 12, 2025, 4:00 PM EDT
7.95
+0.20 (2.58%)
After-hours: Sep 12, 2025, 6:16 PM EDT

Zevra Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
43544527215830848
Upgrade
Market Cap Growth
134.90%63.82%71.57%-48.52%536.60%283.47%
Upgrade
Enterprise Value
29541623397178112
Upgrade
Last Close Price
7.758.346.554.598.7111.20
Upgrade
Forward PE
65.96----2.95
Upgrade
PS Ratio
6.5718.859.9015.5910.743.64
Upgrade
PB Ratio
3.6411.224.392.112.42-0.73
Upgrade
P/TBV Ratio
4.12--2.112.42-
Upgrade
P/FCF Ratio
----29.76-
Upgrade
P/OCF Ratio
----29.47-
Upgrade
EV/Sales Ratio
4.7517.618.499.526.218.43
Upgrade
EV/EBITDA Ratio
----22.27-
Upgrade
EV/EBIT Ratio
----23.01-
Upgrade
EV/FCF Ratio
----17.20-
Upgrade
Debt / Equity Ratio
0.531.520.710.190.01-1.06
Upgrade
Debt / EBITDA Ratio
----0.18-
Upgrade
Debt / FCF Ratio
----0.16-
Upgrade
Asset Turnover
0.310.140.190.080.401.22
Upgrade
Quick Ratio
7.662.351.167.5826.920.90
Upgrade
Current Ratio
7.852.531.187.7227.201.11
Upgrade
Return on Equity (ROE)
3.53%-207.84%-67.23%-26.48%-28.18%-
Upgrade
Return on Assets (ROA)
-18.85%-31.03%-21.55%-12.54%6.70%-27.52%
Upgrade
Return on Capital (ROIC)
-27.82%-52.90%-31.82%-14.28%7.27%-62.18%
Upgrade
Return on Capital Employed (ROCE)
----6.00%-
Upgrade
Earnings Yield
-0.90%-23.70%-16.95%-16.90%-2.78%-26.41%
Upgrade
FCF Yield
-10.69%-15.65%-12.45%-11.88%3.36%-4.08%
Upgrade
Buyback Yield / Dilution
-33.78%-30.46%-2.79%-15.87%-647.72%-114.79%
Upgrade
Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q